These symptoms improve with continuous use, as only 3% and 9% of patients reported nausea with the long- or short-acting GLP-1RA after 6 months of use, respectively (72)
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al
[9] A modified version of CJC-1295 has also been evaluated for its actions on diverse physiological functions
Microdosing and customization Microdosing refers to using smaller or fractional doses, which are lower than therapeutic doses
The angiogenesis data also applies to cardiovascular health
Among participants who continued treatment and reached their maximum tolerated dose during the extension period, average weight loss approached 30% over a longer follow-up